---
title: "KELUN PHARMA: With the arrival of the peak season in the fourth quarter, Yili Chuanning Bio's performance is expected to improve"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/255391302.md"
description: "KELUN PHARMA stated in an institutional research that the demand for the antibiotic sector is stabilizing. Despite price fluctuations, the company has a clear cost advantage. Yili Chuanning Bio expects a significant decline in overall performance this year compared to last year, affected by the market price of penicillin. With the arrival of the peak season in the fourth quarter, performance is expected to improve, and the volume of synthetic biology products in 2026 and the rebound in penicillin prices will bring greater improvement potential"
datetime: "2025-09-01T03:03:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/255391302.md)
  - [en](https://longbridge.com/en/news/255391302.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/255391302.md)
---

# KELUN PHARMA: With the arrival of the peak season in the fourth quarter, Yili Chuanning Bio's performance is expected to improve

KELUN PHARMA stated during an institutional research that the demand side of the antibiotic sector is currently stabilizing. Despite price fluctuations, the company has a clear cost advantage. Meanwhile, Yili Chuanning Bio has made substantial progress in cost reduction through artificial intelligence. Affected by the market price of penicillin, Yili Chuanning Bio's overall performance is expected to decline significantly compared to last year. Currently, the price of penicillin has bottomed out, and with the arrival of the peak season in the fourth quarter, performance is expected to improve. By 2026, with the volume production of synthetic biology products and the rebound in penicillin prices, Yili Chuanning Bio's operating performance and profits are expected to have significant room for improvement

### Related Stocks

- [002422.CN](https://longbridge.com/en/quote/002422.CN.md)
- [301301.CN](https://longbridge.com/en/quote/301301.CN.md)

## Related News & Research

- [Flow Pharma U.S. Patent Application Allowed for Issuance Covering Broad-Spectrum Ebola Therapy](https://longbridge.com/en/news/287076761.md)
- [NEWLY FORMED MANHATTAN URANIUM RECEIVES APPROVAL TO DRILL AT NEVADA'S LARGEST PAST PRODUCING MINE](https://longbridge.com/en/news/287233635.md)
- [11:23 ETTOUS les JOURS BRINGS OFFICIAL BTS THE CITY ARIRANG POP-UP EXPERIENCE TO LAS VEGAS BAKERY CAFÉS](https://longbridge.com/en/news/286793282.md)
- [HSA warns public against consuming herbal remedy containing potent steroid](https://longbridge.com/en/news/287022845.md)
- [US working with small biotech firm on experimental Ebola treatment, Bloomberg News reports](https://longbridge.com/en/news/287108072.md)